Monday, March 21, 2011
The U.K. government is moving
into the next phase of creating a value-based system for pricing branded
medicines that tries to bring into balance what have been mutually exclusive
goals: cost control and improved patient access to drugs.
Depending on how value is
defined and measured, the result could be exactly the opposite of what the
government intends. Conceivably, valued-based prices could end up lower than
U.K. drug prices are now, which could reduce the country's attractiveness as a
place to do R&D and early product launches, which in turn would have a
detrimental effect on patient access to medicines.